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Control of human cytomegalovirus (HCMV) infection is predominantly mediated by cytolytic CD8 T lymphocytes (CTL).
Among the roughly 200 HCMV-encoded polypeptides, the tegument protein pp65 (ppUL83) and the nonstructural IE1 protein
are considered to be dominant CTL targets. Yet the importance of CTL against IE1 for protective immunity against HCMV
reactivation and disease has remained elusive. Analyses have been difficult, as all MHC class I presented peptides of IE1
defined so far are located in parts of the protein that are variable between viral strains. In this study a conserved decameric
peptide from IE1 (P6, IE1354–363) that bound to HLA-A2 was identified. Using peptide-pulsed, HLA-matched stimulator cells,
CTL lines which recognized P6 after exogenous loading as well as after endogenous processing could repeatedly be
generated. However, memory CTL directed against P6 were not readily detectable by ex vivo ELISPOT analysis in peripheral
blood mononuclear cells of healthy seropositive individuals, indicating that this peptide represents a quantitatively subdomi-
nant determinant during latent HCMV infection. Using the conserved HLA-A2 presented peptide P6 will enable more detailed
studies on the role of IE1-specific CTL in patients suffering from various HCMV-related disease conditions and investigation
of the role of such cells for immune control of HCMV. Since IE1 is the first viral protein to be expressed after reactivation
from latency, P6 may also serve as an important component of a future recombinant HCMV vaccine. © 2002 Elsevier Science (USA)INTRODUCTION
Human cytomegalovirus (HCMV) infection is a major
cause of morbidity and mortality in immunosuppressed
patients (Pass, 2001). Studies on allogeneic bone mar-
row and hematopoetic stem cell transplant recipients
have demonstrated a correlation between efficient CD8
T lymphocyte reconstitution and control of HCMV infec-
tion (Reusser et al., 1991; Cwynarski et al., 2001; Gratama
et al., 2001). Adoptive transfer of virus-specific cytotoxic T
lymphocytes (CTL) has been shown to be protective both
in murine and in human cytomegalovirus infections (Red-
dehase et al., 1985; Walter et al., 1995).
Although the HCMV genome has the capacity to en-
code roughly 200 proteins, surprisingly few viral polypep-
tides have been identified as CTL targets (reviewed by
Reddehase, 2000). Early studies characterized the viral
immediate-early regulatory protein IE1 (pUL123) as an
HCMV CTL antigen (Borysiewicz et al., 1988). Subse-
quent analyses denoted the tegument protein pp65
(pUL83) as the dominant CTL target and several pp65
peptide epitopes presented by different HLA molecules© 2002 Elsevier Science (USA)
All rights reserved.
208have been defined (Wills et al., 1996; Boppana and Britt,
1996; Diamond et al., 1997).
Using ex vivo analysis, CTL against both pp65 and IE1
could be detected in significant frequencies in seropos-
itive individuals (Kern et al., 2000; Gyulai et al., 2000).
Kern et al. (2000) determined CTL frequencies against
individual peptides from IE1 and pp65, using intracellular
staining for IFN-. They suggested that the efficiency of
CTL induction by IE1 or pp65 was linked to the present-
ing MHC class I molecules and proposed that the indi-
vidual genetic background may determine an immu-
nodominance of one antigen over the other (Kern et al.,
2000). Gyulai et al. (2000), using limiting dilution analysis
and standard chromium release assays, reported that
CTL against IE1 and pp65 were present in comparable
frequencies in peripheral blood mononuclear cells
(PBMC) of two seropositive donors. In addition, cells
expressing both proteins concomitantly were targeted
with comparable efficiency by IE1- and pp65-specific cell
lines. This contrasts with earlier reports showing that
presentation of IE1-derived peptides was inefficient after
HCMV infection of target cells and was selectively inhib-
ited by pp65 (Gilbert et al., 1993, 1996).
To analyze the interdependence of IE1 and pp65 in
MHC class I-restricted presentation in detail and to studyKey Words: human cytomegalovirus; herpesviruses; im
conserved CTL epitopes.
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peptides from both proteins, which are presented by
identical MHC class I molecules, need to be available.
For pp65, conserved CTL epitopes have already been
defined (reviewed by Reddehase, 2000). One of the most
prominent of these (pp65495–503) is presented by the HLA
class I molecule A*0201, which is frequent in the Cauca-
sian population (Wills et al., 1996; Diamond et al., 1997;
Zaia et al., 2001). In contrast, all peptides that have been
described for IE1 thus far are encoded by polymorphic
regions of the protein that vary between viral strains. The
goal of this study was to define an HLA-A2 presented
peptide of IE1 that was conserved between viral strains.
Using the SYFPEITHI database (Rammensee et al.,
1999), three peptides from IE1 that bound to HLA-A2 with
moderate to high affinity could be identified. Only one of
them, termed P6, was sufficient to stimulate CTL lines
(CTLL) from HLA-A2-positive blood donors. CTL against
this peptide were undetectable without in vitro restimu-
lation, indicating that P6 was a quantitatively subdomi-
nant determinant.
RESULTS
Binding of IE1 peptides to HLA-A2
According to predicted binding motifs for the HLA-
A*0201 molecule, the amino acid sequence of IE1 of
HCMV strain Ad169 was analyzed using the SYFPEITHI
database (Rammensee et al., 1999). Thirteen nonameric
or decameric peptides with a score exceeding 18 were
selected and synthesized (Fig. 1A). All peptides were
tested individually for their capacity to bind to HLA-A2
molecules on the surface of TAP-deficient T2 cells. As a
control, T2 cells were incubated with the nonapeptide
pp65495–503, which is known to bind to HLA-A2 with high
affinity (Wills et al., 1996; Diamond et al., 1997). Addition
of this peptide resulted in twofold enhanced cell surface
expression of MHC class I molecules, detected by indi-
rect cytofluorometric analysis (Fig. 1B). An irrelevant pep-
tide from murine CMV, containing an H-Kd motif, served
as negative control. The binding efficiency of the IE1
peptides to T2 cells varied significantly. Incubation with
peptides P1, P5, and P11–P13 resulted in poor to unde-
tectable enhancement of MHC class I surface expres-
sion. This indicated that these peptides did not bind to
HLA-A2 despite the presence of appropriate binding
motifs (Fig. 1B). Peptides P2–P4 and peptides P6–P8
induced intermediate augmentation of fluorescence,
suggesting moderate affinity to HLA-A2. In contrast, the
addition of peptides P9 and P10 caused distinct stabili-
zation of MHC complexes on the cell surface. Peptide P9
bound with comparable affinity to the positive control
peptide pp65495–503.
Recognition of IE1 peptide-loaded cells by CTLL
Peptide binding to MHC class I molecules has been
successfully used to identify viral CTL epitopes. How-
ever, although peptide MHC complex stability can be an
indicator, not all peptides which bind to the presenting
molecule serve as antigenic peptides during infection in
vivo. To analyze whether those peptides from the HCMV
IE1 protein which showed significant stabilization of
MHC complexes were recognized by CTL from infected
individuals, PBMC from several HLA-A2-positive donors
were isolated and expanded by weekly stimulation with
autologous PHA blasts loaded with P6, P9, or P10 and
supplemented with IL-2.
Stimulation of PBMC from HLA-A2-positive, HCMV an-
tibody-positive donors with peptides P9 or P10, which
stabilized the MHC complexes in a manner comparable
to the positive control pp65495–503, led to the expansion of
cell lines that grew poorly and did not lyse peptide-
loaded target cells. In contrast, stimulation of PBMC with
P6 resulted in cytotoxic T cell lines in two HLA-A2 ho-
mozygous donors (CTLL A-P6 and B-P6) in repeated
experiments. No such cell lines could be generated from
HLA-A2 heterozygous individuals, using P6 for stimula-
tion. Reactivity against P6-pulsed T2 cells or autologous
PHA blasts was detectable after four rounds of in vitro
restimulation. Cytotoxicity further increased after addi-
tional restimulations with peak values after five or six
rounds of restimulation (Fig. 2). To verify that the ob-
served cytotoxicity was indeed stimulated from memory
CTL and was not a result of ex vivo priming, PBMC from
HCMV seronegative individuals were restimulated in
parallel. In these cases the restimulation protocol did not
lead to significant proliferation and expansion of T cells
and specific cytolysis of P6-pulsed targets could never
be detected (data not shown). These findings together
with the observation that no cytotoxicity against the other
IE1-derived peptides could be observed after in vitro
stimulation strongly argue against in vitro priming of
P6-specific CTL by the protocol used.
CTLL A-P6 and CTLL B-P6 were further characterized.
Using peptide-pulsed T2 cells as targets in chromium
release assays (CRA) we could show that the CTLL were
specific for P6. The peptide P10, which is a 1-amino-acid
N-terminal deletion of P6 and still contains an HLA-A2-
binding motif, was not recognized. In order to determine
whether these CTL were secreting IFN- in response to
antigen stimulation, ELISPOT analyses were performed
using CTL A-P6. Incubation of 2  104 IE-1-specific CTL
and 7.5  104 peptide-loaded T2 cells resulted in conflu-
ent spots, indicating that a large proportion of effector
cells released IFN- in response to P6 presentation (Fig.
3). CTLL B-P6 was further used after nine rounds of
stimulation to determine the minimal peptide concentra-
tion that was still sufficient to mediate cytolysis (Fig. 4).
T2 cells were incubated with different concentrations of
P6 and used as targets in CRA with an effector:target
ratio of 25:1. Specific lysis was observed with peptide
209CONSERVED HLA-A2 CTL EPITOPE OF HCMV IE1
concentrations ranging from 105 to 107 M. No specific
lysis was observed when lower peptide concentrations
were used for loading. The requirement of relatively high
peptide concentrations for exogenous loading of target
cells is in accordance with the moderate ability of P6 to
stabilize HLA-A2 surface expression on T2 cells.
FIG. 1. Enhanced surface expression of MHC class I molecules on T2 cells mediated by IE1 peptides. (A) Location of peptides and positions of
mutations with respect to the amino acid sequence of the IE1 protein of HCMV strain Ad169. Each individual peptide is shown as black bar below
the sequence. The location of peptide P6 shown to be reactive with HLA-A2-restricted CTL is accentuated by a boldface bar. Exon boundaries are
depicted on top of the sequence. , amino acids conserved in all strains sequenced to date. , published amino acid substitutions (Chou, 1992;
Retiere et al., 1998; Zweygberg et al., 1998). (B) Schematic representation of the MHC class I stabilization capacity of individual peptides as measured
by the T2 stabilization assay. HLA-A2 stabilization over background staining as analyzed by flow cytometry using the HLA-ABC specific antibody
W6/32 is given as x-fold value. The HLA-A2 presented peptide pp65495–503 was used as positive control; a peptide from MCMV (PmCMV) was used
as negative control.
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To verify that cytolytic activity was indeed restricted by
MHC class I molecules, inhibition experiments using the
monoclonal antibody W6/32 directed against HLA-ABC
were performed. Lysis values were significantly reduced
after preincubation of peptide-pulsed target cells with
W6/32, indicating that the cytolysis was MHC class I
dependent (data not shown).
Cytolysis of HCMV-infected cells by IE1 peptide-
specific CTLL
The results had demonstrated that CTL precursors
specific for peptide P6 were present in the peripheral
blood of HCMV seropositive individuals and that these
cells were able to lyse peptide-loaded targets after in
vitro restimulation with the peptide. To analyze whether
P6 was presented by MHC class I after endogenous
processing of the IE1 protein, HLA-A2-positive human
fibroblasts were treated with 500 U/ml IFN- for 72 h and
were subsequently infected with either the laboratory
strain Ad169 or the pp65 deletion mutant RVAd65
(Schmolke et al., 1995) at an m.o.i. of 1. At 16 h postin-
fection (p.i.), infected cells or mock-infected cells were
used as targets in CRA (Fig. 5). CTL A-P6 lysed target
cells infected with HCMV but failed to lyse mock-infected
cells. Lysis was enhanced after infection with RVAd65,
lacking the pp65 protein. These results show that pep-
tide P6 of IE1 is generated during viral infection and is
presented by HLA-A2 in a manner to mediate cytolysis.
Determination of CTL precursor frequencies to P6
during latent HCMV infection
To analyze the role of P6 in HCMV immunosurveil-
lance during latent infection in vivo, ELISPOT analyses
were performed with PBMC isolated from buffy coats of
healthy, HLA-A2-positive donors. Prior to analysis, the
CD8 T cells of the PBMC were purified using magnetic
separation systems (Miltenyi, Bergisch-Gladbach, Ger-
many). A total of 105 CD8 T cells were seeded per well
in triplicate and coincubated with K562-A2 cells labeled
with 105 M P6. No ex vivo reactivity against P6 could be
detected in effector cells obtained from 14 HCMV sero-
positive and 4 HCMV seronegative donors. However,
cells from 12 of 14 seropositive donors, but not from any
of the seronegative donors, released IFN- after stimu-
lation with the dominant nonapeptide pp65495–503. This
result suggests that the precursor frequency of P6-spe-
cific memory cells was below the detection limit in
healthy subjects, while pp65-specific CTL were readily
detectable in most cases.
DISCUSSION
The regulatory IE1 protein of HCMV is synthesized in
abundance commencing immediately after infection and
continuing throughout the replicative cycle. Early studies
identified IE1 as a target antigen for CD8 CTL (Bory-
siewicz et al., 1988). Subsequent analyses focused on
the tegument protein pp65 as the dominant recognition
element of CTL responses against HCMV (McLaughlin-
Taylor et al., 1994; Boppana and Britt, 1996; Wills et al.,
1996). Employment of novel methodology has recently
confirmed that IE1-specific CTL are present in the pe-
ripheral blood of healthy donors or transplant recipients
(Kern et al., 1999, 2000). This was also suggested by
studies using standard limiting dilution analysis and
chromium release assays on healthy donors and HIV-
infected individuals (Gyulai et al., 2000; Jin et al., 2000).
However, the role of IE1-specific CTL in limiting viral
replication and preventing viral disease still remains
elusive. In particular, there is ongoing discussion
whether pp65 and IE1 induce CTL responses concomi-
tantly and whether this may be important for the control
FIG. 2. Analysis of the presence of P6-specific CTL in HLA-A2-
positive donors. Peripheral blood mononuclear cells were expanded in
culture using autologous PHA blasts pulsed with peptide P6. After six
rounds of restimulation, CTLL were analyzed. (A and B) CTLL were
tested against peptide-pulsed T2 cells (T2  P6) or against T2 cells
without peptide (T2) by a standard 4-h CRA with the indicated effector:
target (E:T) ratios. (A, CTLL A-P6; B, CTLL B-P6). Percentage of cytolysis
was defined as 100 (experimental release  spontaneous release)/
(maximal release  spontaneous release).
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of acute infection or latency (Kern et al., 1999, 2000;
Gyulai et al., 2000; Jin et al., 2000). In vitro experiments
had shown that HCMV-infected target cells are poorly
lysed by IE1-specific T-cell lines and that coexpression of
IE1 and pp65 leads to selective exclusion of IE1 from
MHC class I-restricted presentation (Gilbert et al., 1993,
1996). Kern and colleagues (2000), using cytofluorometric
analysis of IFN- production as readout, found domi-
nance of IE1 or pp65 as CTL antigens in single individ-
uals and ascribed that to presentation of either protein
being linked to the presence of particular HLA mole-
cules. In contrast, recent analysis of CTLL generated
from PBMC of healthy HCMV seropositive individuals
revealed that pp65- and IE1-specific CTL could be de-
tected concomitantly (Gyulai et al., 2000; Jin et al., 2000).
In addition, using limiting dilution analysis combined
with standard CRA, these authors found comparable
frequencies of CTL against pp65 and IE1 in two individ-
uals. However, a truncated version of IE1, shifting the
predominant subcellular localization of the protein from
FIG. 3. Release of IFN- by CTLL B-P6 after stimulation with peptide-loaded T2 cells. ELISPOT assays were carried out using 2  104 IE-1-specific
CTL and 7.5 104 peptide-loaded T2 cells (triplicate). (A) Control, using unloaded T2 cells as target cells. (B) Control, using pp65495–503-loaded T2 cells
as target cells. (C) P6-loaded T2 cells as target cells. The strong P6-specific reactivity led to confluent spots which could not be resolved by computer
assisted video image analysis. In controls (A and B) fewer than 20 spots/well were detectable.
FIG. 4. Determination of the minimal concentration of P6 sufficient to
mediate cytolysis. CTLL B-P6 was tested against T2 cells pulsed with
different peptide concentrations after nine rounds of restimulation with
an effector:target ratio of 25:1 in a standard 4-h CRA. Percentage of
cytolysis was defined as 100 (experimental release  spontaneous
release)/(maximal release  spontaneous release).
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the nucleus to the cytoplasm, was used for the genera-
tion of IE1-specific CTL. The cytoplasmic version of IE1
may be more readily accessible to proteasomal degra-
dation and subsequent MHC class I presentation than
the full-length protein, and this may explain the discrep-
ant results. The key question whether CTL generated
against IE1 add to the control of viral reactivation and
subsequent replication remains to be answered. Further-
more, the mechanisms of how IE1 presentation is influ-
enced by pp65 have not been elucidated in detail. To be
able to approach these issues, we defined a first IE1
peptide to be presented by MHC class I that is con-
served among all 33 viral strains for which the corre-
sponding nucleotide sequence has been determined
(Retiere et al., 1998; Chou, 1992). CTLL could be repeat-
edly generated against P6 from PBMC of two HCMV
seropositive donors using HLA-matched stimulator cells.
These cell lines lysed peptide-loaded cells after four
rounds of stimulation and reached peak cytolytic activity
after six rounds of stimulation. Interestingly, the two do-
nors from which IE1-specific CTLL could be generated
were HLA-A2 homozygous, whereas expansion of such
cells originating from heterozygous donors was not pos-
sible. This is in accordance with a recent report showing
that higher frequencies of HCMV peptide-specific CTL
are found in HLA homozygous as opposed to heterozy-
gous individuals (Gillespie et al., 2000).
We also attempted to establish CTLL from HCMV se-
ronegative, HLA-A2-positive donors, using the same pro-
tocols. These lines generally grew very poorly. On the
rare occasions when enough cells were available for
testing, these lines did not lyse peptide-pulsed target
cells above background, arguing against primary in vitro
generation of P6-specific CTL. In addition, CTLL against
P9 and P10, which bound much more tightly to HLA-A2,
never showed cytolytic activity, emphasizing that the
stimulation protocol used was not particularly prone to in
vitro generation of CTL responses.
Although CTLL could be generated repeatedly from
PBMC of two donors, ex vivo detection of P6-specific CTL
by ELISPOT analysis without culturing in the presence of
peptide was unsuccessful in healthy individuals. Other
investigators have found significant numbers of IE1-spe-
cific CTL both in healthy individuals and in immunosup-
pressed patients. Gyulai et al. (2000) reported compara-
ble frequencies of IE1- and pp65-specific CTL in two
individuals. However, the presenting HLA class I mole-
cules have not been determined. Kern et al. (2000) found
CTL against both proteins in some individuals, but pos-
tulated a correlation of the immunodominance of one of
the two antigens over the other determined by the pre-
senting allomorph. Depending on the HLA type of the
donor, particular peptides from IE1 or pp65 were found to
be preferred CTL targets.
In our study, we found CTL against pp65495–503 using
ELISPOT analysis of CD8 selected T cells from 12
healthy, HLA-A2-positive donors while none were de-
tected against IE1354–363. This would be consistent with
the notion of a preferential presentation of pp65-derived
peptides in HLA-A2-positive individuals. It would thus be
tempting to speculate that pp65-related exclusion of IE1
from HLA class I presentation would be confined to
particular peptides or presenting HLA molecules.
Although binding of P6 to HLA-A2 led to only an inter-
mediate increase in MHC stability compared to other
putative HLA-A2 binders, P6-loaded target cells were
well recognized, indicated by a strong IFN- response,
and these targets were lysed by CTL restimulated with
P6. Similar results have been obtained in a study on
pp65, where the most efficient CTL peptide epitopes
were only moderately active in stabilizing MHC class I
surface expression (Solache et al., 1999). Binding of P6 to
HLA-A2 may be influenced by its structure. P6 is a
decamer. It is thus likely that the peptide bound with its
anchor residues Ile355 and Val363 to HLA-A2, thereby form-
ing an internal loop of one amino acid. This could lead to
less stable binding of P6 to HLA-A2. It would also explain
the different antigenic properties of P6 compared to its
nonameric counterpart P10. P10 would be supposed to fit
into the binding groove of A2 more tightly, thus forming a
different antigenic surface.
Expansion of CTL by restimulation with peptide P6 led
to the generation of cell lines that lysed HCMV-infected
cells, indicating that P6 was generated by endogenous
processing. In addition, cytolysis by these cell lines
could be reduced significantly with an antibody against
HLA-ABC. These results indicate that cytolysis was me-
diated by MHC class I-restricted T lymphocytes. Cytoly-
FIG. 5. Endogenous processing and presentation of peptide P6 after
infection of target cells with HCMV. MRC-5 human fibroblasts were
pretreated with IFN- for 72 h and were subsequently infected at an
m.o.i. of 1 for 16 h with either the laboratory strain Ad169 (MRC-5/
Ad169) or the pp65 deletion mutant RVAd65 (MRC-5/RVAd65) or were
mock infected (MRC-5/mock). CTLL A-P6 was tested in 6-h CRA with
the indicated effector:target (E:T) ratios. Percentage of cytolysis was
defined as 100 (experimental release  spontaneous release)/(max-
imal release  spontaneous release).
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sis of HCMV-infected cells by P6-specific CTLL was low
compared to the highly efficient cytolysis of peptide-
loaded cells. In a previous study, Gilbert et al. (1993)
found that CTLL specific for the IE1 protein lysed HCMV-
infected cells also with relatively low efficiencies varying
between 16 and 28%. The reason for this remains unclear
at this point. However, it is interesting that cells infected
with a pp65 deletion mutant of HCMV were lysed with
higher efficiency than cells infected with the parental
strain Ad169. This would be in line with previous results
showing that coexpression of pp65 and IE1 resulted in
reduced lysis of target cells by IE1-specific CTL (Gilbert
et al., 1996). More detailed studies using P6 as a target
are necessary to investigate this.
Peptide P6-specific CTL appeared to be quantitatively
subdominant in healthy seropositive individuals, as no
IFN- release by CD8 T cells could be detected in ex
vivo analyses. Yet, the quality of the effector CTL re-
sponse against P6 remains to be determined in future
studies. This appears to be an important issue as recent
experiments in the murine CMV (MCMV) model have
shown that qualitative immunodominance and quantita-
tive immunodominance are not necessarily correlated
(Holtappels et al., 2001). In that study, CTL against de-
fined peptides from two viral proteins barely contributed
to the acute immune response and to immunological
memory, yet CTLL generated against these peptides
proved to be highly efficient in resolving the MCMV
infection after adoptive transfer. The authors concluded
that T cell abundance may not be a key criterion for
choosing specificities for immunotherapy and immuno-
prophylaxis. According to this finding, P6 may be a good
candidate for inclusion in an HCMV vaccine strategy,
especially because P6 is located in a region of the IE1
protein that appears to be excluded from genetic varia-
tion. In summary, we have defined an HLA-A2 presented,
conserved decameric peptide from the IE1 protein that is
a target antigen of the CTL response against HCMV. This
peptide can now be used to establish IE1-specific T cell
clones from HLA-A2 transgenic mice. Together with al-
ready established CTL clones against pp65495–503 (Fran-
kenberg et al., unpublished results; Diamond et al., 1997),
such cells will be valuable tools in studying the mecha-
nisms responsible for pp65-mediated IE1 immune eva-
sion. Future studies will have to focus on the role of
IE1354–363 as CTL antigen in patients with HCMV reactiva-
tion and disease. Finally, since IE1 is the first viral protein
to be expressed after reactivation from latency, this pep-




Lymphoid cells were cultured in RPMI 1640 growth
medium (Gibco, Eggenstein, Germany) containing 10%
heat-inactivated FCS, 2 mM glutamine, and 50 mg/liter
gentamycin. K562-A2 cells were cultured in the presence
of G418 (1 mg/ml, Gibco). For the generation and testing
of CTLL, phytohemagglutinin-P (PHA-P; Sigma, Deisen-
hofen, Germany)-activated blasts were established from
autologous PBMC by incubation of PBMC for 3–6 days in
the presence of 5 g of PHA-P per milliliter.
MRC-5 human fibroblasts were maintained in DMEM
(Gibco) supplemented with 10% heat-inactivated FCS, 2
mM glutamine, 1% nonessential amino acids, and 50
mg/liter gentamycin.
Donors
PBMC were derived from healthy HLA-A2-positive
adults. Donors were tested for HCMV serostatus using
commercially available enzyme-linked immunosorbent
assays. Donor A: HLA type, A*0201, B55, B60, Cw3; donor
B: HLA-type, A*0201, B51, B62, Cw9, Cw14.
CTLL
CTLL were established as described previously (Pep-
perl et al., 1998). In brief, PBMC were purified by density
gradient centrifugation with Ficoll-Histopaque (Sigma)
and cultivated in T cell medium [RPMI 1640 growth me-
dium with 10% heat-inactivated human AB serum (PAN,
Aidenbach, Germany) and 2 mM glutamine, 1% nones-
sential amino acids, 2 mM sodium pyruvate, and 50
mg/liter gentamycin]. T lymphocytes were stimulated
once a week with autologous peptide-pulsed, irradiated,
PHA-activated blasts for the generation of HCMV-spe-
cific CTLL at a stimulator:responder ratio of 10:1 and
were supplemented with 20 U of recombinant human
interleukin-2 (PAN) per milliliter. For pulsing of stimulator
cells, peptides were used at concentrations of 1.5 105
M. After 3 to 4 weeks of stimulation, CTLL were first
tested for cytotoxicity.
Synthetic peptides
Using the SYFPEITHI database (http://134.2.96.221), 13
peptides from IE1 with HLA-A*0201-binding motifs were
selected and obtained from Jerini Biotools (Berlin, Ger-
many) (P1, TMYGGISLL; P2, VLAELVKQI; P3, ILDEERDKV;
P4, LLSEFCRVL; P5, SLGDPLFPEL; P6, YILGADPLRV; P7,
LITKPEVISV; P8, CMMTMYGGI; P9, SLLSEFCRV; P10,
ILGADPLRV; P11, MMGGCLQNAL; P12, MMTMYGGISL;
P13, CMKVFAQYIL).
Cytotoxicity assays
Cytotoxicity was tested by standard CRA as described
previously (Pepperl et al., 1998). CRA were performed at
the indicated effector:target ratios with a constant num-
ber (103) of 51Cr-labeled target cells and graded numbers
of effector cells in 0.2-ml round-bottomed 96-microwell
plates. Throughout, the cytolytic activity reported repre-
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sents the mean percentage of specific 51Cr release from
three replicate microcultures. CTL activity directed
against peptides in the context of HLA-A2 was monitored
with HLA-A2-positive T2 cells labeled with peptide at a
final concentration of 5  107 M. Peptide labeling was
performed for 1.5 h at 37°C. Infection of HLA-A2-positive
MRC-5 human fibroblasts for use as target cells in CRA
was carried out as described by others (Diamond et al.,
1997). Briefly, cells were treated with IFN- (R & D Sys-
tems, Wiesbaden, Germany) at a concentration of 500
U/ml for 72 h prior to infection. Subconfluent cells were
infected with strains Ad169 or RVAd65 at a m.o.i. of 1.
CRA was performed at 16 h after infection.
T2 stabilization assay
A total of 2.5  105 T2 cells (ATCC CRL-1992) were
incubated in the presence of 100 M peptide in 250 l
RPMI 1640 medium for 16 h at 37°C. HLA class I mole-
cules were detected by flow cytometry using the anti-
body W6/32 (Dako, Hamburg, Germany).
IFN- ELISPOT Assay
ELISPOT analysis was performed as previously de-
scribed (Herr et al., 1997). Briefly, Multiscreen HA plates
(Millipore, Bedford, MA) were coated with 10 g/ml of
monoclonal anti-human IFN- antibody (1-D1K; Mabtech,
Stockholm, Sweden). Prior to analysis, CD8 T cells were
purified using magnetic separation systems according to
the manufacturer’s instructions (Miltenyi, Bergisch-Glad-
bach, Germany). Effector cells were coincubated in trip-
licate with 75,000 peptide-loaded, HLA-A2-positive anti-
gen-presenting cells per well. For analysis of in vitro
generated responder populations, T2 cells were used as
antigen-presenting cells. For ex vivo analysis of periph-
eral blood-derived CD8 cells, HLA-A2-transfected
K562-A2 were used in an attempt to reduce background
due to alloreactivity (Britten et al., 2002). Peptides were
added at a final concentration of 10 g/ml and cells were
incubated at 37°C in 5% CO2 in a final volume of 100
l/well X-Vivo 15 (Biowhittaker, Verviers, Belgium) for
20 h. Captured cytokine was labeled after incubation for
2 h at 37°C with biotinylated mAb anti-hIFN- (7-B6-1;
Mabtech) at 2 g/ml in PBS/0.5% BSA using an avidin–
peroxidase complex (1/100; Vectastain Elite Kit; Vector,
Burlingame, CA). Peroxidase staining was performed
with 3-amino-9-ethyl-carbozole (Sigma). Spot numbers
were automatically determined with the use of computer-
assisted video image analysis (CVIA, Zeiss-Kontron,
Jena, Germany).
ACKNOWLEDGMENTS
The help of Dr. W. E. Hitzler and his colleagues at the University
Hospital of Mainz Blood Bank Facility is gratefully appreciated. This
work was supported by the Deutsche Forschungsgemeinschaft,
Sonderforschungsbereich 490, by Deutsche Krebshilfe Grant 70-
2427-Hu I, and by Stiftung Rheinland-Pfalz fu¨r Innovation 8312-38 62
61/439.
REFERENCES
Boppana, S. B., and Britt, W. J. (1996). Recognition of human cytomeg-
alovirus gene products by HCMV-specific cytotoxic T cells. Virology
222, 293–296.
Borysiewicz, L. K., Hickling, J. K., Graham, S., Sinclair, J., Cranage, M. P.,
Smith, G. L., and Sissons, J. G. (1988). Human cytomegalovirus-
specific cytotoxic T cells: Relative frequency of stage-specific CTL
recognizing the 72-kD immediate early protein and glycoprotein B
expressed by recombinant vaccinia viruses. J. Exp. Med. 168, 919–
931.
Britten, D. M., Meyer, R. G., Kreer, T., Drexler, I., Wo¨lfel, T., and Herr, W.
(2002). The use of HLA-A*0201-transfected K562 as standard anti-
gen-presenting cells for CD8 T lymphocytes in IFN- ELISPOT
assays. J. Immunol. Methods 259, 95–110.
Chou, S. (1992). Effect of interstrain variation on diagnostic DNA am-
plification of the cytomegalovirus major immediate-early gene re-
gion. J. Clin. Microbiol. 30, 2307–2310.
Cwynarski, K., Ainsworth, J., Cobbold, M., Wagner, S., Mahendra, P.,
Apperley, J., Goldman, J., Craddock, C., and Moss, P. A. (2001). Direct
visualization of cytomegalovirus-specific T-cell reconstitution after
allogeneic stem cell transplantation. Blood 97, 1232–1240.
Diamond, D. J., York, J., Sun, J. Y., Wright, C. L., and Forman, S. J. (1997).
Development of a candidate HLA A*0201 restricted peptide-based
vaccine against human cytomegalovirus infection. Blood 90, 1751–
1767.
Gilbert, M. J., Riddell, S. R., Li, C. R., and Greenberg, P. D. (1993).
Selective interference with class I major histocompatibility complex
presentation of the major immediate-early protein following infection
with human cytomegalovirus. J. Virol. 67, 3461–3469.
Gilbert, M. J., Riddell, S. R., Plachter, B., and Greenberg, P. D. (1996).
Cytomegalovirus selectively blocks antigen processing and presen-
tation of its immediate-early gene product. Nature 383, 720–722.
Gillespie, G. M., Wills, M. R., Appay, V., O’Callaghan, C., Murphy, M.,
Smith, N., Sissons, P., Rowland-Jones, S., Bell, J. I., and Moss, P. A.
(2000). Functional heterogeneity and high frequencies of cytomega-
lovirus-specific CD8() T lymphocytes in healthy seropositive do-
nors. J. Virol. 74, 8140–8150.
Gratama, J. W., van Esser, J. W., Lamers, C. H., Tournay, C., Lowenberg,
B., Bolhuis, R. L., and Cornelissen, J. J. (2001). Tetramer-based quan-
tification of cytomegalovirus (CMV)-specific CD8() T lymphocytes in
T-cell-depleted stem cell grafts and after transplantation may identify
patients at risk for progressive CMV infection. Blood 98, 1358–1364.
Gyulai, Z., Endresz, V., Burian, K., Pincus, S., Toldy, J., Cox, W. I., Meric,
C., Plotkin, S., and Berencsi, K. (2000). Cytotoxic T lymphocyte (CTL)
responses to human cytomegalovirus pp65, IE1-exon4, gB, pp150,
and pp28 in healthy individuals: Reevaluation of prevalence of IE1-
specific CTLs. J. Infect. Dis. 181, 1537–1546.
Herr, W., Linn, B., Leister, N., Wandel, E., Meyer zum Buschenfelde,
K. H., and Wo¨lfel, T. (1997). The use of computer-assisted video
image analysis for the quantification of CD8 T lymphocytes produc-
ing tumor necrosis factor alpha spots in response to peptide anti-
gens. J. Immunol. Methods 203, 141–152.
Holtappels, R., Podlech, J., Grzimek, N. K., Thomas, D., Pahl-Seibert,
M. F., and Reddehase, M. J. (2001). Experimental preemptive immu-
notherapy of murine cytomegalovirus disease with CD8 T-cell lines
specific for ppM83 and pM84, the two homologs of human cytomeg-
alovirus tegument protein ppUL83 (pp65). J. Virol. 75, 6584–6600.
Jin, X., Demoitie, M. A., Donahoe, S. M., Ogg, G. S., Bonhoeffer, S.,
Kakimoto, W. M., Gillespie, G., Moss, P. A., Dyer, W., Kurilla, M. G.,
Riddell, S. R., Downie, J., Sullivan, J. S., McMichael, A. J., Workman, C.,
and Nixon, D. F. (2000). High frequency of cytomegalovirus-specific
cytotoxic T-effector cells in HLA-A*0201-positive subjects during mul-
tiple viral coinfections. J. Infect. Dis. 181, 165–175.
Kern, F., Faulhaber, N., Frommel, C., Khatamzas, E., Prosch, S., Scho-
nemann, C., Kretzschmar, I., Volkmer-Engert, R., Volk, H. D., and
Reinke, P. (2000). Analysis of CD8 T cell reactivity to cytomegalovirus
215CONSERVED HLA-A2 CTL EPITOPE OF HCMV IE1
using protein-spanning pools of overlapping pentadecapeptides.
Eur. J. Immunol. 30, 1676–1682.
Kern, F., Surel, I. P., Faulhaber, N., Frommel, C., Schneider-Mergener, J.,
Schonemann, C., Reinke, P., and Volk, H. D. (1999). Target structures
of the CD8()-T-cell response to human cytomegalovirus: The 72-
kilodalton major immediate-early protein revisited. J. Virol. 73, 8179–
8184.
McLaughlin-Taylor, E., Pande, H., Forman, S. J., Tanamachi, B., Li, C. R.,
Zaia, J. A., Greenberg, P. D., and Riddell, S. R. (1994). Identification of
the major late human cytomegalovirus matrix protein pp65 as a
target antigen for CD8 virus-specific cytotoxic T lymphocytes.
J. Med. Virol. 43, 103–110.
Pass, R. F. (2001). Cytomegalovirus. In “Virology” (D. M. Knipe and P. M.
Howley, Eds.), pp. 2675–2705. Lippincott, Williams and Wilkins, Phil-
adelphia.
Pepperl, S., Benninger-Do¨ring, G., Modrow, S., Wolf, H., and Jilg, W.
(1998). Immediate-early transactivator Rta of Epstein–Barr virus (EBV)
shows multiple epitopes recognized by EBV-specific cytotoxic T
lymphocytes. J. Virol. 72, 8644–8649.
Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and
Stevanovic, S. (1999). SYFPEITHI: Database for MHC ligands and
peptide motifs. Immunogenetics 50, 213–219.
Reddehase, M. J. (2000). The immunogenicity of human and murine
cytomegaloviruses. Curr. Opin. Immunol. 12, 390–396.
Reddehase, M. J., Weiland, F., Mu¨nch, K., Jonjic, S., Luske, A., and
Koszinowski, U. H. (1985). Interstitial murine cytomegalovirus pneu-
monia after irradiation: Characterization of cells that limit viral repli-
cation during established infection of the lungs. J. Virol. 55, 264–273.
Retiere, C., Imbert, B. M., David, G., Courcoux, P., and Hallet, M. M.
(1998). A polymorphism in the major immediate-early gene delin-
eates groups among cytomegalovirus clinical isolates. Virus Res. 57,
43–51.
Reusser, P., Riddell, S. R., Meyers, J. D., and Greenberg, P. D. (1991).
Cytotoxic T-lymphocyte response to cytomegalovirus after human
allogeneic bone marrow transplantation: Pattern of recovery and
correlation with cytomegalovirus infection and disease. Blood 78,
1373–1380.
Schmolke, S., Kern, H. F., Drescher, P., Jahn, G., and Plachter, B. (1995).
The dominant phosphoprotein pp65 (UL83) of human cytomegalovi-
rus is dispensible for growth in cell culture. J. Virol. 69, 5959–5968.
Solache, A., Morgan, C. L., Dodi, A. I., Morte, C., Scott, I., Baboonian, C.,
Zal, B., Goldman, J., Grundy, J. E., and Madrigal, J. A. (1999). Identifi-
cation of three HLA-A*0201-restricted cytotoxic T cell epitopes in the
cytomegalovirus protein pp65 that are conserved between eight
strains of the virus. J. Immunol. 163, 5512–5518.
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S.,
Thomas, E. D., and Riddell, S. R. (1995). Reconstitution of cellular
immunity against cytomegalovirus in recipients of allogeneic bone
marrow by transfer of T-cell clones from the donor. N. Engl. J. Med.
333, 1038–1044.
Wills, M. R., Carmichael, A. J., Mynard, K., Jin, X., Weekes, M. P., Plachter,
B., and Sissons, J. G. (1996). The human cytotoxic T-lymphocyte (CTL)
response to cytomegalovirus is dominated by structural protein
pp65: Frequency, specificity, and T-cell receptor usage of pp65-
specific CTL. J. Virol. 70, 7569–7579.
Zaia, J. A., Gallez-Hawkins, G., Li, X., Yao, Z. Q., Lomeli, N., Molinder, K.,
La Rosa, C., and Diamond, D. J. (2001). Infrequent occurrence of
natural mutations in the pp65(495–503) epitope sequence presented
by the HLA A*0201 allele among human cytomegalovirus isolates.
J. Virol. 75, 2472–2474.
Zweygberg, W. B., Brytting, M., Linde, A., Wahren, B., and Grillner, L.
(1998). Sequence variation within three important cytomegalovirus
gene regions in isolates from four different patient populations.
J. Clin. Microbiol. 36, 3662–3669.
216 FRANKENBERG ET AL.
